Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

First Posted Date
2021-10-28
Last Posted Date
2024-03-26
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
43
Registration Number
NCT05098119
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

First Posted Date
2021-10-22
Last Posted Date
2024-01-16
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
6
Registration Number
NCT05088967
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis

First Posted Date
2021-09-27
Last Posted Date
2022-11-10
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05057052
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

First Posted Date
2021-09-01
Last Posted Date
2023-02-08
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT05029973
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

First Posted Date
2021-08-30
Last Posted Date
2023-07-19
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
60
Registration Number
NCT05026593
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

First Posted Date
2021-08-30
Last Posted Date
2024-11-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT05026736
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Sintilimab in Cancer of Unknown Primary

Phase 2
Active, not recruiting
Conditions
Cancer of Unknown Primary Site
Interventions
Drug: Sintilimab
First Posted Date
2021-08-27
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
12
Registration Number
NCT05024968
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

First Posted Date
2021-08-23
Last Posted Date
2024-12-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT05017103
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

First Posted Date
2021-08-18
Last Posted Date
2023-09-13
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05010681
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

First Posted Date
2021-08-18
Last Posted Date
2023-09-13
Lead Sponsor
Fudan University
Target Recruit Count
25
Registration Number
NCT05010668
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy